Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    EPOR
Show Display Options
Rank Status Study
1 Withdrawn A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies
Condition: Anemia
Intervention: Drug: No intervention
2 Unknown  Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens
Condition: Cancer
Intervention:
3 Completed Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia
Conditions: CABG;   Coronary Artery Disease
Interventions: Drug: Epoetin alpha;   Drug: NaCl 0.9%
4 Completed
Has Results
A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia
Condition: Anemia
Intervention: Drug: Methoxy Polyethylene Glycol-Epoetin Beta
5 Completed
Has Results
A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis
Condition: Anemia
Intervention: Drug: Methoxy polyethylene glycol-epoetin beta
6 Completed A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
7 Completed The Role of Erythropoietin in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention:
8 Completed
Has Results
A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta
9 Completed
Has Results
A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
10 Completed Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction
Condition: Acute Myocardial Infarction
Intervention: Drug: methoxy-polyethyleneglycol epoetin beta
11 Completed Comparison Among Erythropoietin Stimulating Agents
Condition: Anemia of End Stage Renal Disease
Interventions: Drug: Epoetin alpha or beta (Epoetin group);   Drug: Darbepoetin alfa;   Drug: Methoxy polyethylene glycol-epoetin beta
12 Completed
Has Results
A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis
Condition: Anemia
Intervention: Drug: Methoxy polyethylene glycol-epoetin beta
13 Completed
Has Results
A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
14 Completed
Has Results
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
15 Completed
Has Results
A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
16 Completed
Has Results
A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
17 Completed
Has Results
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Condition: Anemia
Intervention: Drug: C.E.R.A.
18 Completed
Has Results
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta
19 Recruiting Molecular Biology of Polycythemia and Thrombocytosis
Conditions: Polycythemia;   Thrombocytosis
Intervention:

Study has passed its completion date and status has not been verified in more than two years.